Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors
Sponsor: FindCure Biosciences (ZhongShan) Co., Ltd.
Summary
This study is a prospective, single-arm, open-label, dose-escalation study. A total of 4 dose groups were pre-defined in this study. The drug was administered once every 6 weeks.The drug would be administered for 1 to 4 cycles. The dosing schedule and dose could also be adjusted according to the patient's condition. After each dose group completed the enrollment and DLT observation, based on the participant's safety tolerance, radiation dosimetry, and preliminary efficacy evaluation results, it was decided whether to adjust the dose of the subsequent dose groups or to suspend the dose escalation.
Official title: Evaluation of the Safety, Dosimetry and Efficacy of 177Lu-INN805 Injection in Patients With Malignant Solid Tumors
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2026-04
Completion Date
2027-03
Last Updated
2026-03-10
Healthy Volunteers
No
Conditions
Interventions
INN805
The drug was administered once every 6 weeks. It was expected that the drug would be administered for 1 to 4 cycles.
Locations (1)
Affiliated Hospital of Jiangnan University
Wuxi, Jiangsu, China